IDIVAL researchers clarify the role of the NF‑κB pathway in this inflammatory disease The research team focused on characterizing Immunoglobulin A–mediated vasculitis from the Immunopathology Group at the Marqués de Valdecilla Research Institute (IDIVAL) has demonstrated that two genes involved in the immune response, NFKB1 and NFKBIA, do not influence the risk of developing this […]
A multidisciplinary team from the Valdecilla Health Research Institute (IDIVAL), the Marqués de Valdecilla University Hospital (HUMV), and the Valdecilla Virtual Hospital has validated, in an animal model, a new dynamic traction device, Dynatract®, designed to improve the treatment of “Open Abdomen,” a severe complication that arises after complex surgeries or severe infections. These patients […]
Dr. Álvaro Díaz-González, attending physician in the Digestive Diseases Department at Marqués de Valdecilla University Hospital and researcher in the Clinical and Translational Research Group on Digestive Diseases at the Valdecilla Research Institute (IDIVAL), is the first author of the new “Clinical Practice Guidelines for the Diagnosis and Treatment of Cholestatic Liver Diseases in Adult […]
The Marqués de Valdecilla Research Institute (IDIVAL), the Cantabrian Health Service (SCS), and Gilead Sciences S.L.U. have formalised a new collaboration agreement aimed at strengthening research, training, and health promotion in the field of viral hepatitis diagnosis in Cantabria. The agreement is framed within Project FOCUS, an international initiative focused on improving screening and linkage […]
Mental health has become one of the major healthcare priorities in Europe, and cooperation between territories is key to making effective and equitable progress. In this context, the Marqués de Valdecilla Health Research Institute (IDIVAL) plays a relevant role in the Joint Action PRISM (JA PRISM), an ambitious European project that brings together 59 organisations […]
The advisory body met to assess scientific progress, human resources and strategic planning The IDIVAL’s External Scientific Advisory Board reviews 2025 activity and the Institute’s main strategic priorities of the Marqués de Valdecilla Health Research Institute (IDIVAL) met at the Marqués de Valdecilla University Hospital to review the activity carried out by the Institute throughout […]
The session focused on alignment with European standards in science, management, and research talent The Valdecilla Health Research Institute (IDIVAL) held an institutional session within the framework of the Santander Biomedical Lectures entitled “HRS4R at IDIVAL: Science, Management and Talent for the European Future”, during which it presented to the research community the update of […]
The Marqués de Valdecilla Health Research Institute (IDIVAL) organized the event “Brussels in Cantabria: Opportunities and Synergies in European Projects”, an initiative aimed at strengthening Cantabria’s participation in European R&D&I programmes and consolidating the regional network of European project managers. The meeting took place at the IDIVAL Building (Avda. Cardenal Herrera Oria s/n, Santander). This […]
Oncologist Fernando Rivera participates in the research published in The New England Journal of Medicine An international study has shown that adding an immunotherapy treatment to standard chemotherapy improves survival in patients with stomach cancer and gastroesophageal junction cancer who are eligible for surgery. The study, entitled “Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer,” […]
The research team from the Valdecilla Research Institute (IDIVAL) and the Directorate-General of Public Health of the Health Department of the Government of Cantabria took part in the European Health Congress held in Finland as part of the JA Prevent NCD project, where they presented the abstract titled “Trends in Tobacco Use Among Primary Care […]
